<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650219</url>
  </required_header>
  <id_info>
    <org_study_id>ID-RCB 2010-A00315-3</org_study_id>
    <nct_id>NCT02650219</nct_id>
  </id_info>
  <brief_title>Auto-antibodies Prevalence and CD1 Role in Gaucher Disease</brief_title>
  <official_title>Prevalence of Autoantibodies in the Gaucher Disease and the Role of CD1 Molecules in Immune Manifestations of This Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypergammaglobulinaemia is frequently observed in type 1 Gaucher disease (GD1), being either
      polyclonal or monoclonal gammopathies. Polyclonal hypergammaglobulinemia may be related to
      the presence of autoantibodies. The clinical significance of such antibodies is questioned in
      Gaucher disease (GD), as some cases of immunologic thrombocytopenia and autoimmune hemolytic
      anemia have also been reported.

      Objectives:

      To evaluate the prevalence of autoantibodies and autoimmune diseases in GD1 patients, we
      conducted a multicenter national study. The investigators investigated whether there was a
      link between splenectomy, genotype, therapeutic options and the presence of these
      autoantibodies.They also investigated whether there was a correlation with some clinical
      manifestations of GD1
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity &lt;15% in Blood Leucocytes Completed When Necsssary by GB1 Mutation Analyses (Analyses From Samples)</measure>
    <time_frame>baseline</time_frame>
    <description>acidβ-glucosidase enzyme testing : a lower than 15% of mean normal activity is considered to be diagnostic.
Decreased enzyme levels will often be confirmed by genetic testing. Numerous different mutations occur; GB1 mutation analyses is sometimes necessary to confirm the diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With : Splenectomy and/or Bone Events and/or Pulmonary Hypertension and/or Specific Treatment and Non-specific (Medical History,Physiological Parameters and Questionnaire)</measure>
    <time_frame>Baseline</time_frame>
    <description>data available from medical record of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With : Photosensitivity and/or Raynaud Phenomenon and/or Sicca Syndrome and/or Arthralgia and/or Arthritis and/or Thrombosis (Medical History and Questionnaire)</measure>
    <time_frame>Baseline</time_frame>
    <description>Features usually associated with auto immune disease- data available from medical record of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With : Antinuclear and/or Anti-SSa and/or Anti-SSb and/or Anti-RNP and/or Anti-DNA and/or Anti-Sm and/or Anticardiolipid and/or Anti β2Gp1 and/or Antiganglioside Autoantibodies (Genetics Analyses From Blood Samples)</measure>
    <time_frame>baseline</time_frame>
    <description>data available from biological analyses (blood samples)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>gaucher disease type 1</arm_group_label>
    <description>Inclusion criteria:
Adult patients &gt;= 18 years old
Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
Patients must have read, understood and signed informed consent. intervention : genetic analyses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>healthy subjects intervention: genetic analyses</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>genetic analyses</intervention_name>
    <arm_group_label>gaucher disease type 1</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        40 GD1 patients and 20 healthy volunteers (control group) were included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        for GD1 patients

        Inclusion Criteria:

          -  Adult patients &gt;= 18 years old

          -  Gaucher disease type 1, proved by low betaglucosidase, with or without treatment

          -  Patients must have read, understood and signed informed consent.

        Exclusion Criteria:

          -  Under 18 years old

          -  Pregnant or breast-feeding

          -  Patients under administrative control

          -  Prisoners

          -  Patients without social rights

          -  Emergency hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Serratrice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St joseph France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Internal Medicine Department, Hôpital Minjoz,</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive Care Department, Hôpital Pellegrin,</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Department, Hôpital Beaujon,</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Clinical Immunology Department, CHU,</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Department, Catholic University,</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Department, CHU, Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Rheumatology Department, Hôpital La Croix Saint Simon,</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Department, CHU la Pitié Salpêtrière,</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>13 Internal Medicine Department, CHU,</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours, Université François Rabelais, INSERM 1069,</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Immunology Department, CHU Hôpital Brabois,</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <results_first_submitted>January 7, 2016</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2016</results_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital St. Joseph, Marseille, France</investigator_affiliation>
    <investigator_full_name>Christine Serratrice</investigator_full_name>
    <investigator_title>MD head of internal medicine department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>from January 2010 to April 2011, 40 GD1 patients and 20 healthy volunteers (control group) were included in the study in the 12 inclusions centers (medical clinic or hopsital)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gaucher Disease Type 1</title>
          <description>Inclusion criteria:
Adult patients &gt;= 18 years old
Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
Patients must have read, understood and signed informed consent. intervention : genetic analyses
genetic analyses</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>healthy subjects intervention: genetic analyses
genetic analyses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gaucher Disease Type 1</title>
          <description>Inclusion criteria:
Adult patients &gt;= 18 years old
Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
Patients must have read, understood and signed informed consent. intervention : genetic analyses
genetic analyses</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>healthy subjects intervention: genetic analyses
genetic analyses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="13.4"/>
                    <measurement group_id="B2" value="47.3" spread="15.4"/>
                    <measurement group_id="B3" value="50.7" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity &lt;15% in Blood Leucocytes Completed When Necsssary by GB1 Mutation Analyses (Analyses From Samples)</title>
        <description>acidβ-glucosidase enzyme testing : a lower than 15% of mean normal activity is considered to be diagnostic.
Decreased enzyme levels will often be confirmed by genetic testing. Numerous different mutations occur; GB1 mutation analyses is sometimes necessary to confirm the diagnosis.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gaucher Disease Type 1</title>
            <description>Inclusion criteria:
Adult patients &gt;= 18 years old
Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
Patients must have read, understood and signed informed consent. intervention : genetic analyses
genetic analyses</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>healthy subjects intervention: genetic analyses
genetic analyses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity &lt;15% in Blood Leucocytes Completed When Necsssary by GB1 Mutation Analyses (Analyses From Samples)</title>
          <description>acidβ-glucosidase enzyme testing : a lower than 15% of mean normal activity is considered to be diagnostic.
Decreased enzyme levels will often be confirmed by genetic testing. Numerous different mutations occur; GB1 mutation analyses is sometimes necessary to confirm the diagnosis.</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With : Splenectomy and/or Bone Events and/or Pulmonary Hypertension and/or Specific Treatment and Non-specific (Medical History,Physiological Parameters and Questionnaire)</title>
        <description>data available from medical record of the patients</description>
        <time_frame>Baseline</time_frame>
        <population>splenectomy testing</population>
        <group_list>
          <group group_id="O1">
            <title>Gaucher Disease Type 1</title>
            <description>Inclusion criteria:
Adult patients &gt;= 18 years old
Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
Patients must have read, understood and signed informed consent. intervention : genetic analyses
genetic analyses</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>healthy subjects intervention: genetic analyses
genetic analyses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With : Splenectomy and/or Bone Events and/or Pulmonary Hypertension and/or Specific Treatment and Non-specific (Medical History,Physiological Parameters and Questionnaire)</title>
          <description>data available from medical record of the patients</description>
          <population>splenectomy testing</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With : Photosensitivity and/or Raynaud Phenomenon and/or Sicca Syndrome and/or Arthralgia and/or Arthritis and/or Thrombosis (Medical History and Questionnaire)</title>
        <description>Features usually associated with auto immune disease- data available from medical record of the patients</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With : Antinuclear and/or Anti-SSa and/or Anti-SSb and/or Anti-RNP and/or Anti-DNA and/or Anti-Sm and/or Anticardiolipid and/or Anti β2Gp1 and/or Antiganglioside Autoantibodies (Genetics Analyses From Blood Samples)</title>
        <description>data available from biological analyses (blood samples)</description>
        <time_frame>baseline</time_frame>
        <population>antinuclear autoantibodies</population>
        <group_list>
          <group group_id="O1">
            <title>Gaucher Disease Type 1</title>
            <description>Inclusion criteria:
Adult patients &gt;= 18 years old
Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
Patients must have read, understood and signed informed consent. intervention : genetic analyses
genetic analyses</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>healthy subjects intervention: genetic analyses
genetic analyses</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With : Antinuclear and/or Anti-SSa and/or Anti-SSb and/or Anti-RNP and/or Anti-DNA and/or Anti-Sm and/or Anticardiolipid and/or Anti β2Gp1 and/or Antiganglioside Autoantibodies (Genetics Analyses From Blood Samples)</title>
          <description>data available from biological analyses (blood samples)</description>
          <population>antinuclear autoantibodies</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gaucher Disease Type 1</title>
          <description>Inclusion criteria:
Adult patients &gt;= 18 years old
Gaucher disease type 1, proved by low betaglucosidase, with or without treatment
Patients must have read, understood and signed informed consent. intervention : genetic analyses
genetic analyses</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>healthy subjects intervention: genetic analyses
genetic analyses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Christine Serratrice</name_or_title>
      <organization>St Joseph Hospital Marseille</organization>
      <phone>0041798731474</phone>
      <email>cserratrice@hotmail.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

